Cyber Resilience Act guidance raises the stakes for connected product suppliers

Tern plc

The latest Cyber Resilience Act guidance makes the direction of travel clear for connected product manufacturers. Security now has to be built in from the start, maintained through the life of the product and backed by clear processes for risk management, vulnerability handling and ongoing support.

Companies can no longer treat security as a box-ticking exercise at launch. They need to show that products can stay secure after deployment, through updates, configuration changes, new integrations and extended use in the field. That raises the bar for execution and increases the importance of scalable security operations.

This is especially relevant in IoT and OT markets, where products often stay in service for years and depend on complex supply chains, third-party software and remote services. In that environment, weak processes create risk over time. Manual controls, fragmented systems and assumptions of trust become harder to defend when regulation expects continuous oversight.

Security decisions have to reflect how products work in the real world, including where they are deployed, what data they process, what systems they connect to and which threats they are likely to face. For businesses operating in connected-device markets, this points to the value of stronger device identity, trusted credentials and secure communications. Without those foundations, it becomes harder to enforce policy, manage updates securely or demonstrate that cyber risks are under control.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search